Amphastar Pharmaceuticals (AMPH) Gross Profit (2013 - 2026)

Amphastar Pharmaceuticals' Gross Profit history runs 14 years deep, the most recent figure standing at $70.3 million for Q1 2026.

• In Q1 2026, Gross Profit fell 17.51% year-over-year to $70.3 million; the TTM figure through Mar 2026 stood at $341.1 million (down 7.55% YoY), while the FY2025 annual figure was $356.1 million, down 4.76% from the prior year.
• Gross Profit was $70.3 million for Q1 2026 at Amphastar Pharmaceuticals, down from $85.7 million in the prior quarter.
• In the past five years, Gross Profit ranged from a high of $108.4 million in Q3 2023 to a low of $55.8 million in Q1 2022.
• Historically, Gross Profit has averaged $82.4 million across 5 years, with a median of $85.7 million in 2025.
• The sharpest annual moves came in 2023 and 2026: Gross Profit soared 85.27% in 2023, then declined 17.51% in 2026.
• A 5-year view of Gross Profit shows it stood at $71.2 million in 2022, then soared by 35.09% to $96.1 million in 2023, then decreased by 9.87% to $86.6 million in 2024, then slipped by 1.13% to $85.7 million in 2025, then decreased by 17.92% to $70.3 million in 2026.
• The last three Gross Profit figures came in at $70.3 million (Q1 2026), $85.7 million (Q4 2025), and $98.6 million (Q3 2025), per Business Quant data.